{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:19:44Z","timestamp":1718065184214},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anaesthesiologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00101-024-01421-5","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T15:01:50Z","timestamp":1715353310000},"page":"421-422","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Die PROCOAG-Studie\u00a0\u2013 zwischen H\u00e4mostase und Thrombose","The PROCOAG trial\u2014Between hemostasis and thrombosis"],"prefix":"10.1007","volume":"73","author":[{"given":"Jan","family":"Wienhold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Grottke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jama.2023.4080","volume":"329","author":"P Bouzat","year":"2023","unstructured":"Bouzat\u00a0P, Charbit\u00a0J, Abback\u00a0PS et\u00a0al (2023) Efficacy and Safety of Early Administration of 4\u2011Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial. JAMA 329:1367\u20131375","journal-title":"JAMA"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","volume":"27","author":"R Rossaint","year":"2023","unstructured":"Rossaint\u00a0R, Afshari\u00a0A, Bouillon\u00a0B et\u00a0al (2023) The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care 27:80","journal-title":"Crit Care"},{"key":"1421_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/ACO.0000000000001349","volume":"37","author":"J Wienhold","year":"2024","unstructured":"Wienhold\u00a0J, Rayatdoost\u00a0F, Sch\u00f6chl\u00a0H, Grottke\u00a0O (2024) Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma. Curr Opin Anaesthesiol 37:101\u2013109","journal-title":"Curr Opin Anaesthesiol"},{"key":"1421_CR4","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1111\/j.1537-2995.2009.02335.x","volume":"49","author":"NM Dunbar","year":"2009","unstructured":"Dunbar\u00a0NM, Chandler\u00a0WL (2009) Thrombin generation in trauma patients. Transfusion 49:2652\u20132660","journal-title":"Transfusion"},{"key":"1421_CR5","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1182\/blood-2011-03-343046","volume":"118","author":"O Grottke","year":"2011","unstructured":"Grottke\u00a0O, Braunschweig\u00a0T, Spronk\u00a0HM et\u00a0al (2011) Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a\u00a0pig model of coagulopathy with blunt liver injury. Blood 118:1943\u20131951","journal-title":"Blood"},{"key":"1421_CR6","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1186\/cc13982","volume":"18","author":"H Sch\u00f6chl","year":"2014","unstructured":"Sch\u00f6chl\u00a0H, Voelckel\u00a0W, Maegele\u00a0M, Kirchmair\u00a0L, Schlimp\u00a0CJ (2014) Endogenous thrombin potential following hemostatic therapy with 4\u2011factor prothrombin complex concentrate: a\u00a07-day observational study of trauma patients. Crit Care 18:R147","journal-title":"Crit Care"}],"container-title":["Die Anaesthesiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-024-01421-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00101-024-01421-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-024-01421-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T16:02:28Z","timestamp":1718035348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00101-024-01421-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1007\/s00101-024-01421-5","relation":{},"ISSN":["2731-6858","2731-6866"],"issn-type":[{"value":"2731-6858","type":"print"},{"value":"2731-6866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"25 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Wienhold gibt an, dass kein Interessenkonflikt besteht. O.\u00a0Grottke gibt folgende potenziellen Interessenkonflikte an: Forschungsf\u00f6rderung von Abiomed, AstraZeneca, Alveron, Bayer Healthcare, Biotest, Boehringer Ingelheim, CSL Behring, Ferring, Octapharma, Novo Nordisk, Nycomed, und Portola. Vortrags- und Beratungshonorare von Abiomed, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, CSL Behring, Octapharma, Sanofi, Shire, Takeda, Pfizer, und Portola.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}